Literature DB >> 18327403

Clinical presentation and time-course of postoperative venous thromboembolism: Results from the RIETE Registry.

Juan Ignacio Arcelus1, Manuel Monreal, Joseph A Caprini, Javier Gutiérrez Guisado, Maria José Soto, Manuel Jesús Núñez, Juan Carlos Alvárez.   

Abstract

There is little literature about the clinical presentation and time-course of postoperative venous thromboembolism (VTE) in different surgical procedures. RIETE is an ongoing, prospective registry of consecutive patients with objectively confirmed, symptomatic acute VTE. In this analysis, we analysed the baseline characteristics, thromboprophylaxis and therapeutic patterns, time-course, and three-month outcome of all patients with postoperative VTE. As of January 2006, there were 1,602 patients with postoperative VTE in RIETE: 393 (25%) after major orthopaedic surgery (145 elective hip arthroplasty, 126 knee arthroplasty, 122 hip fracture); 207 (13%) after cancer surgery; 1,002 (63%) after other procedures. The percentage of patients presenting with clinically overt pulmonary embolism (PE) (48%, 48%, and 50% respectively), the average time elapsed from surgery to VTE (22 +/- 16, 24 +/- 16, and 21 +/- 15 days, respectively), and the three-month incidence of fatal PE (1.3%, 1.4%, and 0.8%, respectively), fatal bleeding (0.8%, 1.0%, and 0.2%, respectively), or major bleeding (2.3%, 2.9%, and 2.8%, respectively) were similar in the three groups. However, the percentage of patients who had received thromboprophylaxis (96%, 76% and 52%, respectively), the duration of prophylaxis (17 +/- 9.6, 13 +/- 8.9, and 12 +/- 11 days, respectively) and the mean daily doses of low-molecular-weight heparin (4,252 +/- 1,016, 3,260 +/- 1,141, and 3,769 +/- 1,650 IU, respectively), were significantly lower in those undergoing cancer surgery or other procedures. In conclusion, the clinical presentation, time-course, and three-month outcome of VTE was similar among the different subgroups of patients, but the use of prophylaxis in patients undergoing cancer surgery or other procedures was suboptimal.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327403     DOI: 10.1160/TH07-10-0611

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

1.  Fever and deep venous thrombosis. Findings from the RIETE registry.

Authors:  Raquel Barba; Pierpaolo Di Micco; Angeles Blanco-Molina; Cristina Delgado; Elena Cisneros; Jaume Villalta; María V Morales; Alessandra Bura-Riviere; Philippe Debourdeau; Manuel Monreal
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

2.  Risk factors and distribution of symptomatic venous thromboembolism in total hip and knee replacements: prospective study.

Authors:  Ljiljana Markovic-Denic; Kristina Zivkovic; Aleksandar Lesic; Vesna Bumbasirevic; Emilija Dubljanin-Raspopovic; Marko Bumbasirevic
Journal:  Int Orthop       Date:  2012-01-04       Impact factor: 3.075

3.  The AVAIL ME study: a multinational survey of VTE risk and prophylaxis.

Authors:  Ali T Taher; Joseph Aoun; Pascale Salameh
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

Review 4.  Landmark trials in thrombotic vascular disease: a critical appraisal of potential practice-changing trials in 2016-2017.

Authors:  Andrea Cervi; James Demetrios Douketis
Journal:  Intern Emerg Med       Date:  2018-07-27       Impact factor: 3.397

5.  Perioperative pharmacologic prophylaxis for venous thromboembolism in colorectal surgery.

Authors:  Steve Kwon; Mark Meissner; Rebecca Symons; Scott Steele; Richard Thirlby; Rick Billingham; David R Flum
Journal:  J Am Coll Surg       Date:  2011-08-25       Impact factor: 6.113

6.  Attitudes to prescribing compression stockings for patients with acute DVT: the MASTER registry.

Authors:  Guido Arpaia; Monica Carpenedo; Riccardo Pistelli; Ornella Mastrogiacomo; Claudio Cimminiello; Giancarlo Agnelli
Journal:  J Thromb Thrombolysis       Date:  2009-03-10       Impact factor: 2.300

7.  Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study.

Authors:  Alex C Spyropoulos; Mohammed Hussein; Jay Lin; David Battleman
Journal:  J Thromb Thrombolysis       Date:  2009-11       Impact factor: 2.300

8.  Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.

Authors:  Antonio Gómez-Outes; Cristina Avendaño-Solá; Ana Isabel Terleira-Fernández; Emilio Vargas-Castrillón
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

9.  Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry.

Authors:  Chiara Piovella; Fabio Dalla Valle; Javier Trujillo-Santos; Raffaele Pesavento; Leonor López; Llorenç Font; Reina Valle; Dolores Nauffal; Manuel Monreal; Paolo Prandoni
Journal:  Intern Emerg Med       Date:  2014-05-17       Impact factor: 3.397

10.  Antithrombotic prophylaxis in the middle East.

Authors:  Samir Arnaout; Hanady R Samaha; Julien Succar; Imad Bou-Akl; Khaled M Musallam; Ali T Taher
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-05-24       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.